Navigation Links
National Stroke Association Teams With Clinical Trial Matching Service CureLauncher
Date:7/23/2013

Bloomfrield Hills, MI (PRWEB) July 23, 2013

Michigan-based CureLauncher (http://www.curelauncher.com), developer of a patent-pending and proprietary clinical trial matching service, today announced an exclusive partnership with the National Stroke Association—a leading educational, prevention and advocacy group for individuals and their families and health care professionals confronting health issues related to strokes.

National Stroke Association members and visitors will be directed to http://www.curelauncher.com, where specially trained relationship managers help individuals find a clinical trial that may offer access to a new diagnostic test, treatment or rehabilitative approach.

“We are thrilled to partner with CureLauncher,” said Jim Baranski, National Stroke Association CEO. “Together, we can make progress in preventing, treating and understanding this challenging condition that impacts so many American families. In particular, clinical medical research is bringing us new diagnostic techniques to identify individuals at risk for stroke, as well as life strategies and other approaches to prevention.”

The power of clinical trials. Nearly 200 million Americans have a chronic disease such as diabetes, heart disease, asthma or cancer. Less than five percent of them know where to find new treatments available in clinical trials according to the Center for Information & Study on Clinical Research Participation (CISCRP). Yet, some of America’s best medical care is available through these clinical trials.

"CureLauncher redefines the approach to clinical trials by putting people and their families first," said David Fuehrer, CureLauncher President, who is also a two-time cancer survivor and active speaker a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
3. International Attendance for Networking and Education at Informex Beyond Manufacturing
4. Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
7. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
8. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
9. PAREXEL International to Present at J.P. Morgan Healthcare Conference
10. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
11. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Esperance Pharmaceuticals Inc. today reported positive results ... in ovarian cancer patients resistant to paclitaxel. EP-100 is ... cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors ... wide range of cancers. Results of ... were presented at the 2015 ASCO Annual Meeting ...
(Date:6/1/2015)... June 1, 2015  Berg, a biopharmaceutical company committed ... presented clinical research from its trials using its cancer ... preclinical data on triple negative breast cancer, at the ... of Clinical Oncology (ASCO), May 29 – June 2 ... BPM 31510 is one of the first cancer drugs ...
(Date:6/1/2015)... , June 1, 2015  Albany ... announced today that it has signed a ... to co-market their structure-based drug discovery services ... part of the three-year agreement, AMRI gains ... expertise and capabilities. HarkerBIO,s customers will be ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Strategies in the US ... their offering. This new 373-page ... comprehensive analysis of the POC clinical chemistry ... requirements, technological trends, competitive landscape, and emerging ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3
... 2008, Abbott,s,( NYSE: ABT ) employee giving in the ... number of participating employees and total dollar contributions,despite difficult ... Abbott,employees (74 percent) participated in the company,s employee giving ... contributed more than $12.6,million to non-profit groups in 2008, ...
... Offering , ... Rochester, New York ... innovator in advanced cardiac safety biomakers and automated QT analysis, ... as its quarter over quarter revenues have grown in excess ...
... Belgium and LUND, Sweden, February 23 , ... of Partial Factor VIII Inhibition in,Patients Undergoing Knee Replacement ... Brussels: THR) and co-development partner,BioInvent International (OMXS: BINV) announce ... Phase II trial with their long-acting anticoagulant,TB-402 for the ...
Cached Biology Technology:Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 2Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 3iCardiac Reports Significant Revenue Growth and Profitability 2iCardiac Reports Significant Revenue Growth and Profitability 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 2ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 4ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 5
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... remains a goal for governments around the world, nuclear ... as recognised at the 2010 nuclear security summit in ... prevent the proliferation of nuclear weapons, but they are ... role science in this field. A new European nuclear ...
... Researchers from the Georgia Institute of Technology have ... of people worldwide from dying of pneumonia each year. ... is a solution to the problem of diagnosing pneumonia, ... for Disease Control and Prevention (CDC). Pneumonia, an ...
... University of Arizona College of Engineering researcher and his ... will be featured in a segment of an upcoming ... will be featured on the episode premiering Thursday night, ... KUAT Channel 6. "WaveLengths" is a quarterly science program ...
Cached Biology News:Enhancing nuclear security: Training and international collaboration 2A better way to diagnose pneumonia 2A better way to diagnose pneumonia 3Planetary exploration robots to be featured on science program 'WaveLengths' 2
... Ion Channel Cell Lines ,High Quality, Functionally-Validated, ... are well known for having a critical ... consequently have a key function in pain, ... ion channels have been investigated in therapeutic ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
... Protein Staining Solution stains proteins ... electrophoresis (detection limit >= 8 ng ... including washing and destaining processes can ... staining of gel (20 min), proteins ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Biology Products: